title: Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas.
abstract: Syndecan-1, a transmembrane proteoglycan, may exert anti-proliferative effects and promote cell growth by binding various growth factors. Malignant epithelial cells often down-regulate their own syndecan-1 production, and are capable of inducing an aberrant syndecan-1 expression in stromal fibroid cells. Decreased tumor cell syndecan-1 levels in human head and neck squamous cell carcinomas indicate poor prognosis, however, no correlation between stromal syndecan-1 expression and clinical parameters has previously been established. By means of immunohistochemistry, we observed a decrease in tumor cell syndecan-1 reactivity in 33/39 oral carcinoma cases, the degree of which, however, correlated only weakly with the clinical outcome (p = 0.097). Conversely, stromal syndecan-1 positivity proved to be a significant risk factor of recurrence (Cox analysis, p = 0.03) and tumor-specific death (p = 0.023) within a 24-month period after operation. Taken together, stromal expression of syndecan-1 is a reliable factor of adverse prognosis in oral carcinomas.
authors.affiliation: 1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
authors.forename: Miklós
authors.initials: M
authors.lastname: Máthé
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Suba
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Németh
authors.forename: Péter
authors.initials: P
authors.lastname: Tátrai
authors.forename: Tibor
authors.initials: T
authors.lastname: Füle
authors.forename: Gábor
authors.initials: G
authors.lastname: Borgulya
authors.forename: József
authors.initials: J
authors.lastname: Barabás
authors.forename: Ilona
authors.initials: I
authors.lastname: Kovalszky
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology / Q000556:secondary / Q000628:therapy; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D009363:Neoplasm Proteins / Q000378:metabolism; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D017154:Stromal Cells / Q000378:metabolism; D016019:Survival Analysis; D053668:Syndecan-1 / Q000378:metabolism*; D014062:Tongue Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; C508241:SDC1 protein, human; D053668:Syndecan-1